// App-Quantinova.ai

295 : Ipilimumab and nivolumab (I+N) as first-line treatment of metastatic renal cell carcinoma (mRCC): A real-world review in North West of England, United Kingdom.

Researchers

Presenter

  • Jennifer Allison

Principal Investigators

  • Richard Griffiths

  • Tom Waddell

  • Manon Rhys Pillai

Medical Centers

  • The Christie NHS Foundation TRUST, Manchester, United Kingdom

  • The Clatterbridge Cancer Centre, Liverpool and Wirral, United Kingdom

  • The Christie NHS Foundation TRUST, Manchester, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Nephrology

Disease

  • Metastatic Renal Cell Cancer

Biomarkers

  • N/A

Drug/Treatment

  • Ipilimumab

  • Nivolumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved